Curie.Bio
Kevin Hart has extensive experience in strategic finance and operations, currently serving in that capacity at Curie.Bio since September 2024. Prior to this role, Kevin held positions in strategic finance at Fi from December 2021 to September 2024, and was an investment banking associate and analyst at Gordon Dyal & Co. Advisory Group LP between October 2018 and December 2021. Kevin began in investment banking as an analyst at Houlihan Lokey from July 2017 to October 2018. Earlier roles include working as an AV technician at the University of Notre Dame's Office of Information Technology, a real estate agent at Chicago Apartment Finders, and an undergraduate research assistant at Hall Research Group. A graduate of the University of Notre Dame with a Bachelor of Business Administration in Finance, Kevin also contributed to the university as a varsity cheerleader, embodying school spirit and engaging in community service.
This person is not in the org chart
This person is not in any teams
Curie.Bio
2 followers
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.